Psychedelinks is a weekly digest of news, business, and culture in the psychedelics industry curated by members of Emerge Law Group’s groundbreaking Psychedelics Industry Group.
Decriminalization, Legalization, & State Efforts
Last week, Hazel Park became the third Michigan city to decriminalize magic mushrooms and other entheogenic substances, with a statewide campaign in the works. The drugs hold promise for treating depression, PTSD and other conditions, but are psychedelics safe?
Georgia lawmakers on Tuesday advanced a bipartisan resolution that calls for the formation of a House study committee to investigate the therapeutic potential of psychedelics like psilocybin and make recommendations for reforms. The legislation, sponsored by House Appropriations Public Safety Subcom…
Oregon Psilocybin Services Act
The Oregon Psilocybin Services Section at the Oregon Health Authority released a new set of proposed rules Friday related to psilocybin products, testing and training programs.
Research, Therapy, & Science
Psychedelics have huge potential to treat a range of mental illnesses. Field Trip Health is one of dozens of companies to leap into a sector reminiscent of the early days of the cannabis craze. But what do investors—and patients—stand to gain?
Here’s why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
Several psychedelic drugs are touted as effective treatments for drug and alcohol abuse. But psilocybin combined with therapy is emerging as the most effective.
Culture
The world of microdosing is a lot bigger than just LSD or mushrooms. Researchers and users explain dosages, effects, and risks.
A growing number of states are considering bills to expand research or access to the drugs.
Subscribe
Subscribe to Psychedelinks to receive essential weekly articles on news, business, and culture in the psychedelics industry, delivered straight to your inbox.